NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $4.01 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.06 +0.05 (+1.25%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sana Biotechnology Stock (NASDAQ:SANA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sana Biotechnology alerts:Sign Up Key Stats Today's Range$3.61▼$4.0250-Day Range$2.68▼$4.0152-Week Range$2.61▼$6.55Volume5.25 million shsAverage Volume3.92 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function. The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials. Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic. Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.AI Generated. May Contain Errors. Read More Sana Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreSANA MarketRank™: Sana Biotechnology scored higher than 46% of companies evaluated by MarketBeat, and ranked 499th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSana Biotechnology has a consensus price target of $9.50, representing about 136.9% upside from its current price of $4.01.Amount of Analyst CoverageSana Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($0.59) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.59% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 11.06, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 3.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentSana Biotechnology has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sana Biotechnology this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows9 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SANA Stock News HeadlinesSana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 2 at 4:35 AM | americanbankingnews.comSana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026July 1 at 9:00 AM | globenewswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 4 at 1:00 AM | Porter & Company (Ad)Sana Biotechnology (NASDAQ:SANA) Shares Up 7.8% - Still a Buy?June 28, 2026 | americanbankingnews.comHarbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific AdvisorJune 12, 2026 | finance.yahoo.comAs the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?June 10, 2026 | msn.comSana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comSana Biotechnology Shareholders Reelect Directors and Ratify AuditorJune 5, 2026 | tipranks.comSee More Headlines SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $4.07 at the beginning of the year. Since then, SANA stock has decreased by 1.5% and is now trading at $4.01. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $552 million in an initial public offering (IPO) on Wednesday, February 3rd 2021. The company issued 23,500,000 shares at a price of $23.00-$24.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings5/11/2026Today7/04/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 12 days, SANA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SANA CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees380Year Founded2018Price Target and Rating Average Price Target for Sana Biotechnology$9.50 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+136.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$244.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.01% Return on Assets-40.68% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book6.68Miscellaneous Outstanding Shares278,290,000Free Float207,606,000Market Cap$1.12 billion OptionableOptionable Beta2.13 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SANA) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHe turned $12,415 into millions. Now he wants to help you.Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...Tim Sykes | SponsoredI have $2.3M saved for retirement. How much can I actually spend each year?If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredWorld’s Largest Investors Are Moving Their Money (Not Into AI)While headlines focus on the next AI IPO, the world's largest investors are moving capital into one asset at t...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
